Nektar Therapeutics (NKTR) Cash from Investing Activities (2010 - 2026)

Nektar Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$350.8 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 902.92% year-over-year to -$350.8 million; the TTM figure through Mar 2026 stood at -$395.7 million (down 336.93% YoY), while the FY2025 annual figure was -$1.2 million, down 100.84% from the prior year.
• Cash from Investing Activities was -$350.8 million for Q1 2026 at Nektar Therapeutics, down from $372000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $130.3 million in Q1 2022 to a low of -$350.8 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged $17.4 million across 5 years, with a median of $40.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities soared 13521.08% in 2022, then slumped 902.92% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at $40.0 million in 2022, then plunged by 56.56% to $17.4 million in 2023, then soared by 246.4% to $60.2 million in 2024, then slumped by 99.38% to $372000.0 in 2025, then slumped by 94398.12% to -$350.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$350.8 million (Q1 2026), $372000.0 (Q4 2025), and -$94.9 million (Q3 2025), per Business Quant data.